CClinicalTrials.gg
Sign In
CompletedNCT03249246Updated Aug 15, 2017

Epidemiology of Sepsis in Turkish ICUs.

An observational study in Sepsis, Septic Shock and Severe Sepsis, sponsored by Nur Baykara. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Nur Baykara · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
1,499
Ages
18 Years and older
Sex
All
01

Study summary

The prevalence and mortality of sepsis in Turkey is not know at large. Turkish Society of Intensive Care Medicine, Sepsis Study Group conducted a multi-centre,point prevalence survey to determine the prevalence, causative micro-organisms and outcome of sepsis in Turkish ICUs.

02

Conditions studied

  • Sepsis
  • Septic Shock
  • Severe Sepsis

Browse trials for

Keywords

  • Sepsis
  • ICU
  • Point prevalence
03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's enrollment of 1,499 is above the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

This is the only study on the registry with Nur Baykara as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients (>18 yr)present on the participating ICU or admitted to participating ICUs on study day

Eligibility criteria

Inclusion Criteria:All patients present on or admitted to participating ICU on study day.

Exclusion Criteria:

  • Age\<18 years
  • Patients who underwent cardiovascular surgery.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
1,499 participants (actual)
Patient registry
No

Groups and cohorts

  • Infection only

    The patients have only infection

    Other: No intervention

  • Infection + SIRS

    Patients have infection plus systemic inflammatory response syndrome (SIRS)

    Other: No intervention

  • Severe sepsis

    Septic patients with newly developed organ dysfunctions

    Other: No intervention

  • Septic shock

    Sepsis plus sepsis related hypotension

    Other: No intervention

Interventions

  • OtherNo intervention
06

What researchers measure

Primary outcomes

  1. Prevalence of sepsis

    The prevalence of sepsis,Severe sepsis and septic shock on study day

    Time frame: Up to 12 weeks.

Secondary outcomes

  1. Mortality rate of sepsis

    Mortality rate of septic shock

    Time frame: Mortality at 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rhodes A, Phillips G, Beale R, Cecconi M, Chiche JD, De Backer D, Divatia J, Du B, Evans L, Ferrer R, Girardis M, Koulenti D, Machado F, Simpson SQ, Tan CC, Wittebole X, Levy M. The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Med. 2015 Sep;41(9):1620-8. doi: 10.1007/s00134-015-3906-y. Epub 2015 Jun 25. PubMed 26109396 ↗
  • Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, Maraki S, Samonis G, Michalopoulos A. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007 Nov;60(5):1124-30. doi: 10.1093/jac/dkm356. Epub 2007 Sep 20. PubMed 17884829 ↗
  • Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K; International Forum of Acute Care Trialists. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72. doi: 10.1164/rccm.201504-0781OC. PubMed 26414292 ↗
  • Baykara N, Akalin H, Arslantas MK, Hanci V, Caglayan C, Kahveci F, Demirag K, Baydemir C, Unal N; Sepsis Study Group. Epidemiology of sepsis in intensive care units in Turkey: a multicenter, point-prevalence study. Crit Care. 2018 Apr 16;22(1):93. doi: 10.1186/s13054-018-2013-1. PubMed 29656714 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03249246
Lead sponsor
Nur Baykara
Collaborators
Turkish Society of Intensive Care, Sepsis Study Group
Responsible party
Nur Baykara (Prof.Dr.Nur Baykara, Turkish Intensive Care Society) — Sponsor-investigator
First posted
Aug 15, 2017
Start date
Jan 27, 2016
Primary completion
Jan 28, 2016
Completion
Feb 27, 2016
Last update
Aug 15, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Sepsis→

Start the discussion